WT1 TCR T cell therapy - Cell Medica

Drug Profile

WT1 TCR T cell therapy - Cell Medica

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Imperial College of Science, Technology and Medicine; University College London
  • Class T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 20 Jul 2017 Cell Therapy catapult initiates enrolment in a phase I/II trial in Acute myeloid leukaemia (Second-line therapy or greater) in United Kingdom (NCT02550535)
  • 20 Jun 2017 Catapult Therapy TCR has been acquired and merged into Cell Medica
  • 20 Jun 2017 Cell Medica plans a phase I/II trial of dominant WT1-TCR cell therapy for Solid tumours in late 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top